Covidien (COV) Receives Media Sentiment Rating of 0.18

Headlines about Covidien (NYSE:COV) have trended somewhat positive recently, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Covidien earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the healthcare company an impact score of 46.6731421708255 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have effected Accern’s scoring:

How to Become a New Pot Stock Millionaire

Covidien (NYSE:COV) remained flat at $$106.71 during midday trading on Monday. The company has a market cap of $48,980.00, a PE ratio of 27.43 and a beta of 1.01. Covidien has a one year low of $65.97 and a one year high of $108.57.

WARNING: “Covidien (COV) Receives Media Sentiment Rating of 0.18” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at

Covidien Company Profile

Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries.

Insider Buying and Selling by Quarter for Covidien (NYSE:COV)

Receive News & Ratings for Covidien Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien and related companies with's FREE daily email newsletter.

Leave a Reply